Pharmaceutical & Biopharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Service, By Region and Competition, 2020-2030F
상품코드:1763886
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 의약품 및 바이오의약품 수탁 제조 시장 규모는 2024년에 130억 5,000만 달러로 평가되었고, 2030년에는 184억 1,000만 달러에 이르고, 예측 기간 중의 CAGR은 6.10%를 나타낼 것으로 전망됩니다.
개발·제조 수탁기관(CDMO)은 제약회사나 바이오테크놀러지 기업에 있어서 불가결한 파트너가 되어 있어 의약품의 제제화, 원약(API) 제조, 상업규모의 제조 등의 기능을 제공합니다. 이 동향은 특히 바이오의약품 분야에서 현저하고, 생물 제제, 바이오시밀러, 세포 및 유전자 치료제의 제조는 복잡하기 때문에 첨단 기술과 엄격한 품질 기준이 필요합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
130억 5,000만 달러
시장 규모 : 2030년
184억 1,000만 달러
CAGR : 2025-2030년
6.10%
급성장 부문
활성 제약 성분(API)
최대 시장
북미
시장 성장 촉진요인
건강 관리 산업의 성장
주요 시장 과제
바이오의약품 제조의 복잡성
주요 시장 동향
세포 및 유전자 치료 제조에 대한 주목의 고조
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 COVID-19가 세계의 의약품 및 바이오의약품 수탁 제조 시장에 미치는 영향
제5장 세계의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
금액별
시장 점유율·예측
제품 유형별(활성 의약품 원료(API), 완제 의약품, 첨단 약물 전달 제품, 일반 의약품(OTC) 등)
서비스별(의약품 제조 서비스, 바이오의약품 제조 서비스, 의약품 개발 서비스, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
시장 점유율·예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
시장 점유율·예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 의약품 및 바이오의약품 수탁 제조 시장 전망
시장 규모와 예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
합병과 인수
제품 출시
최근 동향
제13장 혼란 : 분쟁, 유행, 무역 장벽
제14장 세계의 의약품 및 바이오의약품 수탁 제조 시장 : SWOT 분석
제15장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제16장 경쟁 구도
Jubilant Pharmova Limited
JRS PHARMA GmbH & Co.
Boehringer Ingelheim GmbH
Lonza Group
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
INCOG BioPharma Services
Baxter Biopharma Solutions
Catalent Pharma Solutions
Kemwell Biopharma Private Limited
제17장 전략적 제안
제18장 기업 소개와 면책사항
KTH
영문 목차
영문목차
The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market was valued at USD 13.05 Billion in 2024 and is projected to reach USD 18.41 Billion by 2030, growing at a CAGR of 6.10% during the forecast period. Contract Development and Manufacturing Organizations (CDMOs) have become indispensable partners for pharmaceutical and biotechnology companies, offering capabilities in drug formulation, active pharmaceutical ingredient (API) production, and commercial-scale manufacturing. Increasingly, companies are outsourcing these operations to reduce capital investments, improve speed to market, and maintain agility in the face of evolving regulatory frameworks and market conditions. This trend is especially pronounced in the biopharmaceutical sector, where the complexity of producing biologics, biosimilars, and cell and gene therapies necessitates advanced technologies and rigorous quality standards. Although growth prospects are robust, market players must contend with rising regulatory complexity and the need for continuous investment in compliance infrastructure.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 13.05 Billion
Market Size 2030
USD 18.41 Billion
CAGR 2025-2030
6.10%
Fastest Growing Segment
Active Pharmaceutical Ingredients (API)
Largest Market
North America
Key Market Drivers
Growth in Healthcare Industry
The rapid expansion of the global healthcare sector, generating over USD 4 trillion in annual revenue, is a significant growth driver for the pharmaceutical and biopharmaceutical contract manufacturing market. With pharmaceuticals and biotechnology contributing nearly USD 850 billion and medical technology and diagnostics adding over USD 400 billion, the healthcare industry is witnessing a growing need for efficient drug production and scalable manufacturing capabilities. To meet these demands, drug developers are increasingly outsourcing to CDMOs, allowing them to focus on R&D and commercialization while leveraging external partners' infrastructure and regulatory expertise. The high costs and long development timelines associated with new drug development-ranging between USD 314 million and USD 4.46 billion-further incentivize the use of contract manufacturers to manage costs, accelerate production, and ensure compliance with evolving regulatory standards.
Key Market Challenges
Complexity in Biopharmaceutical Manufacturing
Biopharmaceutical manufacturing presents considerable complexity, making it a critical challenge for contract manufacturing organizations. Unlike conventional small-molecule drugs, biopharmaceuticals-such as monoclonal antibodies, vaccines, and cell and gene therapies-are derived from living organisms, making their production highly sensitive to variables like temperature, pH, and raw material quality. This complexity necessitates precise control of upstream and downstream processes, as even minor deviations can compromise product safety and efficacy. Consequently, CDMOs must make substantial investments in advanced infrastructure, process optimization, and quality management systems. These demands often lead to longer development cycles and increased operational costs, requiring CDMOs to maintain high levels of expertise and resource allocation.
Key Market Trends
Increased Focus on Cell and Gene Therapy Manufacturing
A defining trend in the market is the rising focus on cell and gene therapy manufacturing. With 76 such therapies launched globally by the end of 2023-more than double the number from a decade prior-this segment is gaining traction due to its promise of targeted, curative treatments for complex diseases. Unlike traditional drug manufacturing, cell and gene therapies involve highly specialized, patient-specific processes that require stringent quality control, cutting-edge bioprocessing, and regulatory precision. Due to these challenges, pharmaceutical companies are increasingly partnering with CDMOs that possess proven capabilities in handling advanced therapeutic modalities. These partnerships enable faster development timelines, greater scalability, and improved regulatory compliance, reinforcing the role of CDMOs as strategic allies in the evolving therapeutic landscape.
Key Market Players
Jubilant Pharmova Limited
JRS PHARMA GmbH & Co.
Boehringer Ingelheim GmbH
Lonza Group
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
INCOG BioPharma Services
Baxter Biopharma Solutions
Catalent Pharma Solutions
Kemwell Biopharma Private Limited
Report Scope
In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type:
Active Pharmaceutical Ingredients (API)
Finished Dosage Formulation
Advanced Drug Delivery Products
Over the Counter (OTC) Medicines
Others
Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service:
Pharmaceutical Manufacturing Services
Biologics Manufacturing Services
Drug Development Services
Others
Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market.
Available Customizations
Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market
5. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others)
5.2.2. By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Service
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Service
6.3.2. Mexico Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Service
6.3.3. Canada Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Service
7. Europe Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Service
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Service
7.3.2. Germany Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Service
7.3.3. United Kingdom Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Service
7.3.4. Italy Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Service
7.3.5. Spain Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Service
8. Asia Pacific Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Service
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Service
8.3.2. India Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Service
8.3.3. South Korea Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Service
8.3.4. Japan Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Service
8.3.5. Australia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Service
9. South America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Service
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Service
9.3.2. Argentina Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Service
9.3.3. Colombia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Service
10. Middle East and Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Service
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Service
10.3.2. Saudi Arabia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Service
10.3.3. UAE Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Service
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions : Conflicts, Pandemics and Trade Barriers
14. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market: SWOT Analysis
